Novartis’ KAE609 shows promise as next generation treatment for malaria
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.